Skip to main content
Clinical Trials/IRCT2013091914715N1
IRCT2013091914715N1CompletedPhase 2

Efficacy and safety of oral tranexamic acid in Melasema

Vice Chancellor for Reasearch of Tehran University of Medical Sciences0 sites100 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 65 years (—)
Sex
All

Inclusion Criteria

  • Inclusion criteria : Age between 18 - 65 years old ; Symmetric distribution of melasma ; Informed consent.
  • Exclusion criteria : Usage of hydroquinone ,topical or oral retinoids ,topical corticosteroid ,alfa hydroxyl acids or other drugs effective to skin pigmentation 3 months prior to the study ; Usage of peeling agents 3 months prior to the study ; Laser therapy 3 months prior to the study ; Sunburn , high exposure to sunlight or solarium usage 3 months prior to the study ; Usage of oral contraceptive concurrently ; Personal or familial history of vitiligo or other pigmentation disorders ; Suspected Hypersensitivity to hydroquinone or trenaxemic acid ; Pregnancy or lactation ; History of ischemic heart disease or cerebrovascular disease ; History of coagulation disorders or deep vein thrombosis ; Usage of aspirin or Plavix.

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Vice Chancellor for Reasearch of Tehran University of Medical Sciences

Similar Trials

Efficacy and safety of oral tranexamic... | Clinical Trial